The role of DNA methylation in the pathogenesis and treatment of cancer

Current Clinical Pharmacology

Volumn 7, Issue 4, 2012, Pages 333-340

  Peedicayil, Jacob ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Cancer; DNA; Methylation; Pathogenesis; Treatment

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; BIOCHANIN A; CATECHIN; CYTOTOXIC AGENT; DAIDZEIN; DISULFIRAM; DNA METHYLTRANSFERASE INHIBITOR; EPICATECHIN; EPIGALLOCATECHIN GALLATE; FISETIN; FLUCYTOSINE DEOXYRIBOSIDE; GENISTEIN; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; ISOFLAVONE; LENALIDOMIDE; MG 98; MITHRAMYCIN; MITOXANTRONE; MYRICETIN; N PHTHALOYLTRYPTOPHAN; PARTHENOLIDE; PROCAINAMIDE; PROCAINE; QUERCETIN; UNINDEXED DRUG; VALPROIC ACID; ZEBULARINE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL CYCLE REGULATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CPG ISLAND; DNA METHYLATION; DNA REPLICATION; DNA SEQUENCE; DRUG MECHANISM; ENZYME INHIBITION; ENZYME SUBSTRATE; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HUMAN; IONIZING RADIATION; LIVER CANCER; LUNG CANCER; MOUTH SQUAMOUS CELL CARCINOMA; MYELODYSPLASTIC SYNDROME; NEOPLASM; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; SIGNAL TRANSDUCTION; SKIN CANCER; SOLID TUMOR; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

EID: 84867783393     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488412803305858     Document Type: Article

References (80)

1. Morin PJ, Trent JM, Collins FS, Vogelstein B. In: Harrison's Principles of Internal Medicine; Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Eds. McGraw-Hill, New York 2012; pp. 663-672.
2. Pugh JE, Holliday R. Do chemical carcinogens act by altering epigenetic controls through DNA repair rather than by mutations? Heredity 1978; 40: 329.
3. Holliday R. A new theory of carcinogenesis. Br J Cancer 1979; 40: 513-522.
4. Pollack Y, Stein R, Razin A, Cedar H. Methylation of foreign DNA sequences in eukaryotic cells. Proc Natl Acad Sci USA 1980; 77: 6463-6467.
5. Lapeyre JN, Becker FF. 5-methylcytosine content of nuclear DNA during chemical hepatocarcinogenesis and in carcinomas which result. Biochem Biophys Res Commun 1979; 87: 698-705.
6. Feinberg A, Vogelstein B. Hypomethylation of ras oncogenes in primary human cancers. Biochem Biophys Res Commun 1983; 111: 47-54.
7. Lapeyre JN, Walker MS, Becker FF. DNA methylation and methylase levels in normal and malignant mouse hepatic tissues. Carcinogenesis 1981; 2: 873-878.
8. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301: 89-92.
9. Allis CD, Jenuwein T, Reinberg D. In: Epigenetics; CD Allis, T Jenuwein, D Reinberg, Eds. Cold Spring Harbor Laboratory Press, New York 2007; pp. 23-61.
10. Li E, Bird A. DNA methylation in mammals. In: Epigenetics; CD Allis, T Jenuwein, D Reinberg, Eds. Cold Spring Harbor Laboratory Press, New York 2007; pp. 341-356.
11. Costello JF, Plass C. Methylation matters. J Med Genet 2001; 38: 285-303.
12. Cheng X, Blumenthal RM. Mammalian DNA methyltransferases: A structural perspective. Structure 2008; 16: 341-350.
13. El-Maarri O, Kareta MS, Mikeska T, et al. A systematic search for DNA methyltransferase polymorphisms reveals a rare DNMT3L variant associated with subtelomeric hypomethylation. Hum Mol Genet 2009; 18: 1755-1768.
14. Suetake I, Shinozaki F, Miyagawa J, Takeshima H, Tajima S. DNMT3L stimulates the DNA methylation activity of Dnmt3A and Dnmt3B through a direct interaction. J Biol Chem 2004; 279: 27816-27823.
15. Nabel CS, Kohli RM. Demystifying DNA demethylation. Science 2011; 333: 1229-1230.
16. Ito S, Shen L, Dai Q, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011; 333: 1300-1303.
17. He Y-F, Li B-Z, Liu P. et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011; 333: 1303-1307.
18. De Carvalho DD, You JS, Jones PA. DNA methylation and cellular programming. Trends Cell Biol 2010; 20: 609-617.
19. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev 2011; 25: 1010-1022.
20. Ballestar E, Wolffe AP. Methyl-CpG-binding proteins. Targeting specific gene repression. Eur J Biochem 2001; 268: 1-6.
21. Schalkwyk LC, Meaburn EL, Smith R, et al. Allelic skewing of DNA methylation is widespread across the genome. Am J Hum Genet 2010; 86: 196-212.
22. Gal-Yam EN, Saito Y, Egger G, Jones PA. Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med 2008; 59: 267-280.
23. Beck S, Rakyan VK. The methylome: approaches for global DNA methylation profiling. Trends Genet 2008; 24: 231-237.
24. McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation: Molecular mechanisms and clinical implications. Clin Cancer Res 2009; 15: 3927-3937.
25. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
26. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-2054.
27. Veeck J, Esteller M. Breast cancer epigenetics: From DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia 2010; 15: 5-17.
28. Esteller M. Epigenetic gene silencing in cancer: The DNA hypermethylome. Hum Mol Genet 2007; 16: R50-R59.
29. Peedicayil J. DNA methylation and the central dogma of molecular biology. Med Hypotheses 2005; 64: 1243-1244.
30. Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000; 60: 2368-2371.
31. You YH, Li C, Pfeifer GP. Involvement of 5-methylcytosine in sunlight-induced mutagenesis. J Mol Biol1999; 293: 493-503.
32. Kanai Y, Ushijima S, Tsuda H, et al. Aberrant DNA methylation precedes loss of heterozygosity on chromosome 16 in chronic hepatitis and liver cirrhosis. Cancer Lett 2000; 148: 73-80.
33. Palusczak J, Baer-Dubowska W. Epigenetic diagnostics of cancerthe application of DNA methylation markers. J Appl Genet 2006; 47: 365-375.
34. Mulero-Navarro S, Esteller M. Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 2008; 68: 1-11.
35. Laird PW. The power and promise of DNA methylation markers. Nat Rev Cancer 2003; 3: 253-266.
36. Shivapurkar N, Toyooka S, Toyooka KO, et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumour types. Int J Cancer 2004; 109: 786-792.
37. Friedrich MG, Weisenberger DJ, Cheng JC, et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 2004; 10: 7457-7465.
38. Dulaimi E, Hillinck J, Ibanez de Caceres I, et al. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 2004; 10: 6189-6193.
39. Stefansson OA, Jonasson JG, Olafsdottir K, et al. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. Epigenetics 2011; 6: 638-649.
40. Yoon H-Y, Kim Y-W, Kang H-W, et al. DNA methylation of GSTP1 in human prostate tissues: Pyrosequencing analysis. Korean J Urol 2012: 53: 200-205.
41. Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res 2003; 9: 2673-2677.
42. Jeronimo C, Usadel H, Henrique R, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 2002; 60: 1131-1135.
43. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001; 61: 249-255.
44. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999; 59: 67-70.
45. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000; 60: 5954-5958.
46. Brim H, Kumar K, Nazarian J, et al. SLC5A8 gene, a transporter of butyrate: A gut flora metabolite, is frequently methylated in African American colon adenomas. PLoS One 2011; 6: e20216.
47. Coley HM, Hatzimichael E, Blagden S, et al. Polo like kinase 2 tumour suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer. Oncotarget 2012; 3: 78-83.
48. Issa J-PJ. DNA methylation as a therapeutic target in cancer. Clin Cancer Res 2007; 13: 1634-1637.
49. Medina-Franco JL, Caulfield T. Advances in the computational development of DNA methyltransferases. Drug Discov Today 2011; 16: 418-423.
50. Van Emburgh BO, Robertson KD. In: Epigenetics; Jorg Tost, Ed. Caister Academic Press, Norfolk, UK 2008; pp 23-61.
51. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006; 5: 37-50.
52. Issa J-PJ, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res 2009; 15: 3938-3946.
53. Streeseman C, Brueckner B, Musch T, Stopper H, Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 2006; 66: 2794-2800.
54. Amatori S, Bagaloni I, Donati B, Fanelli M. DNA demethylating antineoplastic strategies: A comparative point of view. Genes Cancer 2010; 1: 197-209.
55. Fenaux P. Inhibitors of DNA methylation: Beyond myelodysplastic syndromes. Nature Clin Practice Oncol 2005; 2: S36-S44.
56. Matouová M, Votruba I, Otmar M, Tlouová E, Günterová J, Mertliková-Kaiserová H. 2'-deoxy-5,6-dihydro-5-azacytidine-A less toxic alternative of 2'-deoxy-5-azacytidine. Epigenetics 2011; 6: 769-776.
57. Andersen JB, Factor VM, Marquardt JU, et al. An integrated genomic and pharmacoepigenomic approach predicts therapeutic response of zebularine in human liver cancer. Sci Transl Med 2010; 2: 54-77.
58. Beumer JH, Eiseman JL, Parise RA, et al. Concentrations of the DNA methyltransferase inhibitor 5-Fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother Pharmacol 2008; 62: 363-368.
59. Gao Z, Xu Z, Hung MS, et al. Procaine and procainamide inhibit the Wnt canonical pathway by promoter demethylation of WIF-1 in lung cancer cells. Oncol Rep 2009; 22: 1479-1484.
60. Candelaria M, Gallardo-Rincón D, Arce C. et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol 2007; 18: 1529-1538.
61. Kato K, Long NK, Makita H. et al. Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral squamous cell carcinoma cells. Br J Cancer 2008; 99: 647-654.
62. Balasubramanian S, Adhikary G, Eckert RL. The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival. Carcinogenesis 2010; 31: 496-503.
63. Brueckner B, Garcia Boy R, Siedlecki P. et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 2005; 65: 6305-6311.
64. Anderson KN, Bejcek BE. Parthenolide induces apoptosis in glioblastomas without affecting NF-kappa _. J Pharmacol Sci 2008; 106: 318-320.
65. Li Y, Liu L, Andrews LG, Tollefsbol TO. Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms. Int J Cancer 2009; 125: 286-296.
66. Parker BS, Cutts SM, Nudelman A, Rephaeli A, Phillips DR, Sukumar S. Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3 sigma in breast cancer cells. Cancer Biol Ther 2003; 2: 259-263.
67. Lin RK, Hsu CH, Wang YC. Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells. Anticancer Drugs 2007; 18: 1157-1164.
68. Lin J, Haffner MC, Zhang Y. et al. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate 2011; 71: 333-343.
69. Peedicayil J. Epigenetic therapy-A new development in pharmacology. Indian J Med Res 2006; 123: 17-24.
70. Yan L, Nass SJ, Smith D, Nelson WG, Herman JG, Davidson NE. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor _ (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther 2003; 2: 552-556.
71. Plummer R, Vidal L, Griffin M. et al. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase1, given as a 7-day infusion in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 3177-3183.
72. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007; 104: 15805-15810.
73. Shervington A, Patel R. Silencing DNA methyltransferase (DNMT) enhances glioma chemosensitivity. Oligonucleotides 2008; 18: 365-374.
74. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53: 615-627.
75. Peedicayil J. In: Handbook of Epigenetics: The New Molecular and Medical Genetics; Trygve O. Tollefsbol, Ed. Elsevier: London 2011; pp 511-517.
76. Suzuki M, Shinohara F, Nishimura K, Echigo S, Rikiishi H. Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma. Int J Oncol 2007; 31: 1449-1456.
77. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108: 3271-3279.
78. Kaminskyy VO, Surova OV, Vaculova A, Zhivotovsky B. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. Carcinogenesis 2011; 32: 1450-1458.
79. Sekeres MA, O'Keefe C, List AF, et al. Demonstration of additional benefit in adding lenalidomide to azacytidine in patients with higher-risk myelodysplastic syndromes. Am J Hematol 2011; 86: 102-103.
80. Kim WJ, Vo QN, Shrivastav M, Lataxes TA, Brown KD. Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line. Oncogene 2002; 21: 3864-3871.